Mabion S.A. (MAB.WA)
PLN 9.49
(-4.33%)
PLN 9.49
(-4.33%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.94 Million PLN | -29.69% |
| 2022 | 4.19 Million PLN | 91.11% |
| 2021 | 2.19 Million PLN | -30.19% |
| 2020 | 3.14 Million PLN | -21.72% |
| 2019 | 4.01 Million PLN | 17.64% |
| 2018 | 3.41 Million PLN | -18.07% |
| 2017 | 4.16 Million PLN | 8579.17% |
| 2016 | 48 Thousand PLN | -69.03% |
| 2015 | 155 Thousand PLN | 142.19% |
| 2014 | 64 Thousand PLN | 0.0% |
| 2013 | - PLN | 0.0% |
| 2012 | - PLN | 0.0% |
| 2011 | - PLN | 0.0% |
| 2010 | - PLN | 0.0% |
| 2009 | - PLN | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 186 Thousand PLN | -17.33% |
| 2024 Q3 | 133 Thousand PLN | -9.52% |
| 2024 Q2 | 2.34 Million PLN | -20.97% |
| 2023 Q4 | 2.94 Million PLN | -21.6% |
| 2023 Q3 | 3.76 Million PLN | 5.15% |
| 2023 FY | 2.94 Million PLN | -29.69% |
| 2023 Q1 | 3.93 Million PLN | -6.08% |
| 2023 Q2 | 3.57 Million PLN | -9.19% |
| 2022 FY | 4.19 Million PLN | 91.11% |
| 2022 Q4 | 4.19 Million PLN | -8.03% |
| 2022 Q3 | 4.55 Million PLN | 74.34% |
| 2022 Q2 | 2.61 Million PLN | -9.17% |
| 2022 Q1 | 2.87 Million PLN | 31.22% |
| 2021 Q4 | 2.19 Million PLN | -1.3% |
| 2021 Q3 | 2.22 Million PLN | 2.77% |
| 2021 Q2 | 2.16 Million PLN | -23.51% |
| 2021 FY | 2.19 Million PLN | -30.19% |
| 2021 Q1 | 2.82 Million PLN | -10.02% |
| 2020 Q1 | 3.51 Million PLN | -12.58% |
| 2020 FY | 3.14 Million PLN | -21.72% |
| 2020 Q2 | 3.38 Million PLN | -3.68% |
| 2020 Q3 | 2.83 Million PLN | -16.3% |
| 2020 Q4 | 3.14 Million PLN | 11.06% |
| 2019 Q3 | 2.98 Million PLN | -13.28% |
| 2019 Q4 | 4.01 Million PLN | 34.51% |
| 2019 Q2 | 3.44 Million PLN | 16.68% |
| 2019 Q1 | 2.95 Million PLN | -13.57% |
| 2019 FY | 4.01 Million PLN | 17.64% |
| 2018 Q3 | 3.61 Million PLN | -4.87% |
| 2018 FY | 3.41 Million PLN | -18.07% |
| 2018 Q4 | 3.41 Million PLN | -5.59% |
| 2018 Q2 | 3.8 Million PLN | -8.65% |
| 2018 Q1 | 4.16 Million PLN | -0.14% |
| 2017 FY | 4.16 Million PLN | 8579.17% |
| 2017 Q1 | 1.05 Million PLN | 2095.83% |
| 2017 Q2 | 1.41 Million PLN | 34.35% |
| 2017 Q3 | 2.68 Million PLN | 89.27% |
| 2017 Q4 | 4.16 Million PLN | 55.45% |
| 2016 FY | 48 Thousand PLN | -69.03% |
| 2016 Q2 | 138 Thousand PLN | -10.97% |
| 2016 Q3 | 99 Thousand PLN | -28.26% |
| 2016 Q4 | 48 Thousand PLN | -51.52% |
| 2016 Q1 | 155 Thousand PLN | 0.0% |
| 2015 FY | 155 Thousand PLN | 142.19% |
| 2015 Q4 | 155 Thousand PLN | 198.08% |
| 2015 Q3 | 52 Thousand PLN | -18.75% |
| 2015 Q2 | 64 Thousand PLN | 0.0% |
| 2015 Q1 | 64 Thousand PLN | 0.0% |
| 2014 FY | 64 Thousand PLN | 0.0% |
| 2014 Q4 | 64 Thousand PLN | 0.0% |
| 2014 Q2 | - PLN | 0.0% |
| 2014 Q1 | - PLN | 0.0% |
| 2014 Q3 | - PLN | 0.0% |
| 2013 Q1 | - PLN | 0.0% |
| 2013 Q2 | - PLN | 0.0% |
| 2013 Q3 | - PLN | 0.0% |
| 2013 Q4 | - PLN | 0.0% |
| 2013 FY | - PLN | 0.0% |
| 2012 Q4 | - PLN | 0.0% |
| 2012 FY | - PLN | 0.0% |
| 2012 Q3 | - PLN | 0.0% |
| 2011 FY | - PLN | 0.0% |
| 2010 FY | - PLN | 0.0% |
| 2009 FY | - PLN | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bioceltix S.A. | 76.33 Thousand PLN | -3762.026% |
| BIOTON S.A. | 12.67 Million PLN | 76.745% |
| Captor Therapeutics Spolka Akcyjna | 1.24 Million PLN | -136.407% |
| Molecure S.A. | 4.97 Million PLN | 40.753% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 114 Thousand PLN | -2485.965% |
| Poltreg S.A. | 7.8 Million PLN | 62.21% |
| Pure Biologics Spólka Akcyjna | 12.85 Million PLN | 77.062% |
| Ryvu Therapeutics S.A. | 365 Thousand PLN | -707.671% |
| Synthaverse S.A. | 61.2 Million PLN | 95.183% |
| Urteste S.A. | 312 Thousand PLN | -844.872% |